

Supplemental online content for:


Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis

Erwei Zeng, MSc; Wei He, PhD; Karin E. Smedby, MD, PhD; and Kamila Czene, PhD


J Natl Compr Canc Netw 2022;20(6):683–689.e2

eFigure 1: Flowchart of Study Population

eFigure 2: Disease-Free Survival Among Patients Who Discontinued Versus Continued AHT



eFigure 1. Flowchart of study population.
Abbreviation: AHT, adjuvant hormone therapy.



Number at risk	
Continued AHT	2,898 2,737 2,481 2,187 1,914 1,599 1,324 1,082 833 583 360 200 96
Discontinued AHT	2,979 2,793 2,453 2,178 1,861 1,581 1,291 1,034 803 598 392 229 106

eFigure 2. Disease-free survival among patients who discontinued versus continued AHT (matched).

Discontinuers of AHT were 1:1 matched to patients who continued therapy on the index date (date of treatment discontinuation) on age at diagnosis, diagnosis year (± 3 years), primary tumor size, and lymph node metastasis. Patients were followed from the treatment discontinuation until death, emigration, or end of the study period (September 17, 2020), whichever came first. Multivariable model was additionally adjusted for menopause status, baseline type of AHT, use of hormone replacement therapy, Charlson comorbidity score, tumor grade, and progesterone receptor status. Abbreviations: aHR, adjusted hazard ratio; AHT, adjuvant hormone therapy.